Panacea Biotec Secures $8.9 Million Order Expansion from UNICEF

Panacea Biotec (NSE: PANACEABIO) has announced a significant upward revision to its existing supply contract with UNICEF for its WHO pre-qualified pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib). This update reinforces the company’s position as a critical global supplier of pediatric immunization solutions. Key Financial Highlights The total additional award value is approximately $8.93 million (₹80 crore), distributed across the following fiscal tranches: FY 2026 Expansion: The contract value for 2026 has been increased by $2.55 million, bringing the total for that year to $16.8 million. FY 2027 Expansion: The existing 2027 commitment was increased by $2.70 million, totaling $15.18 million. New 2027 Award: UNICEF issued an additional new award for 2027 valued at $3.68 million. Strategic Context and Market Position This expansion follows a robust trend in international procurement for Panacea. In October 2025, the company secured a long-term agreement for bivalent Oral Polio Vaccine (bOPV) supply extending through March 2030. These consecutive awards underscore the company's operational reliability and the high regulatory standing of its manufacturing facilities. Market Performance Following the announcement, shares of Panacea Biotec closed at ₹359.50 on the NSE on December 24, 2025, reflecting a steady gain of 0.93%. The continued influx of multi-year international orders provides strong revenue visibility and enhances the company’s valuation outlook as it enters the 2026 fiscal year. Investment Takeaway: The increased order volume from a primary global agency like UNICEF validates Panacea’s product efficacy and supply chain resilience, offering a stabilized cash flow profile for the 2023–2027 contract period.